Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Myelodysplastic Syndromes 999Leukemia, Myeloid, Acute 826Leukemia, Myelogenous, Chronic, BCR-ABL Positive 532Leukemia 519Precursor Cell Lymphoblastic Leukemia-Lymphoma 501Myeloproliferative Disorders 438Lymphoma, Non-Hodgkin 339Multiple Myeloma 327Hodgkin Disease 313Leukemia, Lymphocytic, Chronic, B-Cell 304Leukemia, Myelomonocytic, Chronic 299Primary Myelofibrosis 285Lymphoma 267Leukemia, Myeloid, Chronic-Phase 254Leukemia, Myeloid, Accelerated Phase 208Blast Crisis 208Lymphoma, Mantle-Cell 206Lymphoma, Follicular 204Burkitt Lymphoma 200Lymphoma, Large B-Cell, Diffuse 192Lymphoma, B-Cell, Marginal Zone 184Congenital Abnormalities 166Lymphoma, Large-Cell, Immunoblastic 165Polycythemia Vera 162Myelodysplastic-Myeloproliferative Diseases 159Neoplasms, Plasma Cell 152Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 145Anemia, Refractory, with Excess of Blasts 127Thrombocythemia, Essential 125Lymphoma, T-Cell, Cutaneous 124

Interventions

ivosidenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × IDH1 Mutation Myeloid Neoplasms × Myeloid × Clear all
NCT03564821 2025-11-04

IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation

Massachusetts General Hospital

Phase 1 Completed
18 enrolled
Myeloid

IDH1 Mutation Myeloid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡